CARBOGEN AMCIS announces major investments of €90 mn in Switzerland and France

CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers.

Aug 14, 2020 02:08 IST India Infoline News Service

Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France.

Dishman Carbogen Amcis Ltd shares slipped over 4% on the BSE in the afternoon session. The scrip opened at Rs195.10 and has touched a high and low of Rs196.85 and Rs184.65 respectively.

CARBOGEN AMCIS announces two major expansion projects that will increase manufacturing capacity to better meet the demands of the current market and its customers. The new facilities, located in Switzerland and France, will be phased in over the next four years, totaling investments in excess of CHF 100m (over €90 million). This follows six years of constant growth for the company. In Switzerland, the project will be initiated in 2021 with construction of a new API manufacturing facility at its Hunzenschwil site.

This project will progress in several phases. It is planned for this new unit to be operational by summer 2024.

“The facility is designed to provide space for CARBOGEN AMCIS to grow over the next 10 years with the initial phase comprising of 12 new vessels (from 630 liters to 4000 liters) and associated filtration and drying capabilities,” said Stephan Fritschi, vice president of operations. “We have an impressive pipeline, and now our customers can benefit from more diverse offerings.”

In addition to the new Swiss API manufacturing facility, additional investments are planned with a dedicated budget to improve some of the existing technologies and to increase the capacity of the current Swiss sites, such as adding chromatography equipment, new reactors in production and new laboratories.

The new French site will be able to supply both clinical batches up to phase III and small-scale for commercial. There will be two automated lines: the first one for both liquid filling plus lyophilization and the second one dedicated to liquid forms. In addition, state-of-the-art development and analytical laboratories will be incorporated to support customer projects. Operations will commence during Q1 of 2023.

Related Story